hotspot -WSS

hotspot

author：focus 2025-10-01 14:59:27 - browse：13

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Weight loss drug costs may need more research, senator suggests

explore

Wikipedia

WSS

Community addresses injustice for Long Island mothers

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Why medical students are struggling with mental health

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Ransomware attacks on hospitals: Study outlines patient impact

entertainment

hotspot

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

State Dept. review finds Biden bears some blame for Afghanistan failures

Grail is spending more than ever lobbying Congress

Duchenne breakthrough therapy leaves behind pioneering families

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Guidelines to prevent youth baseball injuries need more muscle

U.K. considers world's first use of meningitis vaccine to address gonorrhea

New air purifier tech could be key to improving indoor air quality

Morphosys mixed study results for blood cancer drug

focus

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

David Sabatini, ex

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

World's first CRISPR

Listen: PBM conflicts, RSV vaccines, & the future of flu season

Childhood cancer progress stalls for Black, Hispanic kids: Report

knowledge

explore

Wikipedia

Wikipedia